About NeoPhore
NeoPhore is a company based in Cambridge (United Kingdom) founded in 2017 by Chris Torrance, Alberto Bardelli, and Giovanni Germano. It operates as a HealthTech. NeoPhore has raised $44.56 million across 5 funding rounds from investors including Bristol-Myers Squibb, Liftt and Sixth Element Capital. The company has 10 employees as of April 30, 2022. NeoPhore offers products and services including Small Molecule Drugs. NeoPhore operates in a competitive market with competitors including Metabolon, TScan Therapeutics, Lyell Immunopharma, Maze Therapeutics and Hummingbird Bioscience, among others.
- Headquarter Cambridge, United Kingdom
- Employees 10 as on 30 Apr, 2022
- Founders Chris Torrance, Alberto Bardelli, Giovanni Germano
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neophore Limited
- Date of Incorporation 09 May, 2017
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.56 M (USD)
in 5 rounds
-
Latest Funding Round
$12.2 M (USD), Series B
Feb 01, 2024
-
Investors
Bristol-Myers Squibb
& 10 more
-
Employee Count
10
as on Apr 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NeoPhore
NeoPhore offers a comprehensive portfolio of products and services, including Small Molecule Drugs.
Small molecule drugs are developed for cancer neoantigen evolution.
People of NeoPhore
Unlock access to complete
Unlock access to complete
Funding Insights of NeoPhore
NeoPhore has successfully raised a total of $44.56M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $12.2 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NeoPhore
NeoPhore has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Liftt and Sixth Element Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Claris Ventures is engaged in early-stage biotech venture investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for NeoPhore
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NeoPhore
Investment portfolio details for NeoPhore
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NeoPhore
Detailed financials for NeoPhore
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neophore Comparisons
Peer comparison for NeoPhore
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NeoPhore
NeoPhore operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, TScan Therapeutics, Lyell Immunopharma, Maze Therapeutics and Hummingbird Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
Detailed competitors of NeoPhore
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neophore
Complete news archive for NeoPhore
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NeoPhore
NeoPhore was founded in 2017.
NeoPhore is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
NeoPhore is a funded company, having raised a total of $44.56M across 5 funding rounds to date.
As of Apr 30, 2022, the latest employee count at NeoPhore is 10.
NeoPhore is engaged in the discovery and design of small molecule drugs targeting cancer neoantigen evolution. The company aims to develop effective and well-tolerated medicines as part of next-generation cancer immunotherapies. Solutions are designed to stimulate immunity directly at the core of cancer, addressing cancers lacking DNA mismatch repair genes. The approach is centered on creating robust and sustained immune responses in the healthcare sector, specifically within biotechnology and cancer treatment.
NeoPhore's top competitors include Hummingbird Bioscience, Lyell Immunopharma and Maze Therapeutics.
NeoPhore offers Small Molecule Drugs.
NeoPhore has 11 investors. Key investors include Bristol-Myers Squibb, Liftt, Sixth Element Capital, Claris Ventures, and Astellas Venture Management.